J&J Experimental Drug Effective in Psoriasis

by Rajshri on  May 17, 2008 at 3:44 PM Drug News
RSS Email Print This Page Comment bookmark
Font : A-A+

 J&J Experimental Drug Effective in Psoriasis
An experimental drug called ustekinumab made by Johnson & Johnson has proved safe and effective in prevent psoriasis progression for one year or more in two trials.

The first study involved 1, 766 patients and lasted for 76 weeks. Each patient was given either 45-milligram or 90-milligram injections of the drug at the start of the trial and again on week 4 and then one dose every 12 weeks. Another group received a placebo injection.

"Onset of efficacy was rapid, with higher proportions of ustekinumab-treated patients achieving at least 50 percent improvement" researchers said.

In the second trial 1,230 patients were tested for 52 weeks. In 28 weeks, researchers found that 23 percent of patients in the low-dose drug group and 16 percent in the high-dose group had a 75 percent reduction in symptoms.

Both studies appear in The Lancet.

Source: Medindia
RAS/L

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity Iodine Deficiency Disorder Signature Drug Toxicity Psoriasis 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

Advertisement

News Category

News Archive